FDA APPROVES REDUCED MONITORING TIME FOR FIRST TWO DOSES OF IMDELLTRA®

The FDA approved a reduced monitoring time for the first two doses of IMDELLTRA®, decreasing it from 22-24 hours to 6-8 hours, facilitating broader access in community oncology settings for patients with extensive-stage small cell lung cancer in the U.S.

This Wire brief sits within Fusion42's coverage of Biotech.